文献速递湿疹皮炎与荨麻疹

特应性皮炎早期干预与疾病修饰:现状与进展障碍

Early intervention and disease modification in atopic dermatitis-the current state of the field and barriers to progress.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-12-08

特应性皮炎是高患病率慢性炎症性皮肤病和全球残疾负担的重要来源。类风湿关节炎和克罗恩病中疾病修饰治疗显示初始治疗方式与时机可影响长期结局,但早期干预能否改变特应性皮炎病程和共病尚不明确。本文综述疾病修饰策略进展,指出特应性皮炎相关研究缺乏,早期数据提示早期干预的选择与时机可能影响长期病程和共病,需更多研究。

要点

  • 早期干预的选择与时机可能影响特应性皮炎长期病程与共病。
  • 特应性皮炎领域疾病修饰研究缺乏,现有研究存在明显局限。
  • 未来需明确最有效干预路径并扩展至更多共病与更长期结局。

核心结论

  • 早期数据提示早期干预的选择与时机可能影响特应性皮炎长期病程和共病发展,但需更多研究验证。

研究设计与样本

  • 本文为综述,回顾疾病修饰策略进展,重点讨论常见炎症性疾病中的早期干预方法。

主要发现

  • 疾病修饰治疗在类风湿关节炎和克罗恩病中显示初始治疗方式与时机影响长期结局。
  • 皮肤科对疾病修饰策略的研究日益增多,但特应性皮炎相关研究缺乏。
  • 已完成和正在进行的特应性皮炎研究存在显著局限,早期数据仍具前景。

临床怎么用

  • 临床应关注特应性皮炎早期干预的时机与治疗选择对长期病程和共病的潜在影响。

局限性

  • 特应性皮炎领域疾病修饰研究缺乏,现有研究存在显著局限,长期与共病结局证据不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atopic dermatitis (AD) is a highly prevalent chronic inflammatory skin disease representing a major source of global disability burden. Disease-modifying therapies are showing promise in chronic inflammatory disorders such as rheumatoid arthritis and Crohn's disease with method and timing of initial treatment impacting long-term disease outcomes. Whether disease-modifying therapies, specifically those used as an early interventional approach, impacts disease course and comorbidity development in AD is not well-understood. We reviewed the progress in disease modification strategies, emphasizing early intervention approaches in common (or proto-typical) inflammatory diseases. Although more common in other fields, disease modification approaches are becoming increasingly investigated in dermatology, though studies in AD are lacking. Despite significant limitations in ongoing and completed studies, early data are promising and suggest that both the choice and timing of early intervention approach can affect long-term disease course and comorbidity development. To best improve AD patient outcomes, more research is needed to further explore the impact of early disease-modifying therapies. Future studies should focus on identifying the most effective approaches and extend the early results to a more inclusive set of comorbidities and longer-term outcomes.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Jacobson ME, Seshadri RS, Morimoto R, et al. Early intervention and disease modification in atopic dermatitis-the current state of the field and barriers to progress. J Eur Acad Dermatol Venereol. 2023. PMID: 38063244. doi:10.1111/jdv.19699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。